Carcinogenesis Advance Access originally published online on July 19, 2006
Carcinogenesis 2006 27(12):2434-2441; doi:10.1093/carcin/bgl069
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs


1 National Key Laboratory of Biotherapy and Cancer Center, West China Hospital Guo Xue Xian No. 37, Chengdu, Sichuan 610041, People's Republic of China
2 Department of Gynecology and Obstetrics, Second West China Hospital, West China Medical School, Sichuan University Guo Xue Xian No. 37, Chengdu, Sichuan 610041, People's Republic of China
*To whom correspondence should be addressed. Fax: +86 28 85250731; Email: yuquawei{at}vip.sina.com or xia-zhao{at}126.com
Mesenchymal stem cells (MSCs) were adenovirally engineered to secrete interleukin-12 (AdIL-12-MSCs) and evaluated for their anticarcinogenesis efficacy against three kinds of unestablished tumor models including B16 melanoma, LLC Lewis lung cancer and HCC hepatoma. Injection of AdIL-12-MSCs into protected mice before tumor inoculation prevented all of 12 mice in B16 preventive groups, 10 out of 12 in LLC lung cancer model and 11 out of 12 mice in HCC hepatoma model from developing tumors, whereas the control groups pre-receiving PBS were validated for 100% carcinogenesis; the tumor formation rates in free-AdIL-12 and vacant MSC groups were unveiled between
83 and 100% even with plentiful angiogenesis and newborn lymphatic vessels, as well as distant metastases. As a novel approach, AdIL-12-MSC has revealed expected preventive effects on carcinogenesis (P < 0.01) with low-toxic, broad-spectrum and long-range superiorities. In conclusion, our data indicate that AdIL-12-MSC possess the potential for tropism to preclinical tumor lesions and deprives surviving or hibernating tumor cells, which have escaped from conventional treatments, of revival and recurrence.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. R. Loebinger, E. K. Sage, and S. M. Janes Mesenchymal Stem Cells as Vectors for Lung Disease Proceedings of the ATS, August 15, 2008; 5(6): 711 - 716. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Eliopoulos, M. Francois, M.-N. Boivin, D. Martineau, and J. Galipeau Neo-Organoid of Marrow Mesenchymal Stromal Cells Secreting Interleukin-12 for Breast Cancer Therapy Cancer Res., June 15, 2008; 68(12): 4810 - 4818. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lazennec and C. Jorgensen Concise Review: Adult Multipotent Stromal Cells and Cancer: Risk or Benefit? Stem Cells, June 1, 2008; 26(6): 1387 - 1394. [Abstract] [Full Text] [PDF] |
||||


